BUZZ-Oncolytics Biotech Inc: Orphan status for fallopian tube cancer drug
** Canadian biotech company's U.S. shares up 17 pct at $0.84 premarket
** Says the U.S. FDA granted lead drug Reolysin orphan status for treatment of fallopian tube cancer
** Reolysin also being tested for other cancer indications, including breast, pancreatic and head or neck cancers, in multiple studies
** Drug also been given orphan drug status for treatment of ovarian cancer and pancreatic cancer last month
** Orphan drug status granted to drugs developed to treat rare diseases; gives drug developer incentives, including 7-year marketing exclusivity
** Up to Friday's close, stock rose 36 pct this year
© Thomson Reuters 2017 All rights reserved.